fda glp-1 enforcement news today approves first pill for obesity from Wegovy maker Novo Nordisk FDA unveils new safeguard in

Complessivamente l8% dei pazienti ha interrotto la terapia per effetti avversi (contro il 3% del placebo), nel 5% specificamente per effetti gastrointestinali

10.2337/dc06-2375

Yes, restarting treatment usually involves beginning again with a low dose and working upward under medical supervision

Severe nausea may occur, particularly after the first dose

In the placebo group, typical total consumption over 30 days declined by 46%, much less but still a substantial amount, reflecting the placebo effect, the desire to reduce drinking, and the fact that participants received CBT therapy over the course of the trial

[DOI] [PMC free article] [PubMed] [Google Scholar] 149.Nagashima M., Watanabe T., Terasaki M., Tomoyasu M., Nohtomi K., Kim-Kaneyama J